FDA
-
-
-
-
-
-
-
Satellos Announces IND Submission to the U.S. FDA and Global Regulatory Filings to Advance a Phase 2 Clinical Trial of SAT-3247 in Children with Duchenne Muscular Dystrophy
-
-
-
-
-
-
-
Satellos Bioscience Announces 2023 Year End Financial Results and Operational Highlights
324,307 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

